Discovery of Orally Available Prodrugs of the Glutamate Carboxypeptidase II (GCPII) Inhibitor 2-Phosphonomethylpentanedioic Acid (2-PMPA)
- 10 March 2016
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (6) , 2810-2819
Abstract
2-Phosphonomethylpentanedioic acid (1, 2-PMPA) is a potent inhibitor of glutamate carboxypeptidase II which has demonstrated robust neuroprotective efficacy in many neurological disease models. However, 1 is highly polar containing a phosphonate and two carboxylates, severely limiting its oral bioavailability. We strategized to mask the polar groups via a prodrug approach, increasing the likelihood of passive oral absorption. Our initial strategy was to cover the phosphonate with hydrophobic moieties such as pivaloyloxymethyl (POM) and isopropyloxycarbonyloxymethyl (POC) while keeping the α- and γ-carboxylates unsubstituted. This attempt was unsuccessful due to the chemical instability of the bis-POC/POM derivatives. Addition of α,γ-diesters and α-monoesters enhanced chemical stability and provided excellent oral exposure in mice, but these mixed esters were too stable in vivo, resulting in minimal release of 1. By introducing POC groups on both the phosphonate and α-carboxylate, we synthesized Tris-POC-2-PMPA (21b), which afforded excellent release of 1 following oral administration in both mice and dog.Keywords
Funding Information
- National Cancer Institute (RO1CA161056)
- Institute of Organic Chemistry and Biochemistry AS CR, v.v.i.
This publication has 36 references indexed in Scilit:
- Pharmacokinetics and Pharmacodynamics of the Glutamate Carboxypeptidase II Inhibitor 2-MPPA Show Prolonged Alleviation of Neuropathic Pain through an Indirect MechanismThe Journal of Pharmacology and Experimental Therapeutics, 2013
- Glutamate Carboxypeptidase II2013
- The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathyJournal of the Neurological Sciences, 2006
- Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain – relation to brain concentrationNeuropharmacology, 2006
- Synthesis of N-Acetylaspartylglutamate (NAAG) and N-Acetylaspartate (NAA) in Axons and Glia of the Crayfish Medial Giant Nerve Fiber2006
- The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophreniaTrends in Pharmacological Sciences, 2005
- Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis modelsProceedings of the National Academy of Sciences, 2003
- GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor ratsJournal of the Neurological Sciences, 2002
- Mechanisms for clearance of released N-acetylaspartylglutamate in crayfish nerve fibers: Implications for axon–glia signalingNeuroscience, 2001
- Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injuryNature Medicine, 1999